Frontiers in Toxicology, published by Frontiers Media SA, is a prominent open-access journal dedicated to advancing the understanding of toxicological science. Established in 2019, it serves as a vital forum for innovative research, offering insights into the pharmacological impacts and toxicological profiles of various substances. With its international reach based in Switzerland, this journal has quickly ascended in the academic community, achieving a notable Q1 ranking in Pharmacology, Toxicology and Pharmaceutics (Miscellaneous) and a Q2 ranking in Toxicology as of 2023. The journal is indexed in Scopus, where it ranks #8 out of 43 in its primary category, underscoring its influence and relevance in the field. The scope encompasses cutting-edge studies on the mechanisms of toxicity, including both human and environmental impacts, making it an essential resource for researchers, professionals, and students alike. By promoting open access to high-quality research, Frontiers in Toxicology plays a crucial role in enhancing knowledge sharing and fostering collaboration across disciplines.

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

Environmental Toxicology and Pharmacology, published by Elsevier, is a leading journal dedicated to advancing our understanding of the effects of environmental pollutants on biological systems. With an ISSN of 1382-6689 and an E-ISSN of 1872-7077, this journal covers a wide range of studies related to toxicology, pharmacology, and environmental health. The journal is classified as Q2 in key categories such as Health, Toxicology and Mutagenesis and Medicine (miscellaneous), and sits impressively in Q1 for Toxicology, reflecting its strong impact in the field. As of 2023, it ranks #30 out of 133 in Toxicology and #40 out of 148 in Health, indicating its high relevance and contribution to research. While the journal is not currently open access, it remains a pivotal resource for researchers, professionals, and students seeking to explore the intricacies of environmental health effects. Its commitment to publishing high-quality peer-reviewed research positions it as a crucial platform for scientific dialogue and discovery.

TOXICOLOGICAL SCIENCES, published by Oxford University Press, is a premier journal in the field of toxicology that has been a cornerstone of scientific discourse since its inception in 1981. With an impressive 2023 impact factor and ranked in the Q1 category for Toxicology, this journal is highly regarded among researchers, professionals, and students dedicated to pharmacology and toxicology. The journal is committed to advancing the understanding of toxicological science, covering a breadth of topics that include the mechanisms of toxicity, risk assessment, and the regulatory aspects affecting public health. With an ISSN of 1096-6080 and an E-ISSN of 1096-0929, TOXICOLOGICAL SCIENCES facilitates open access scholarly work, ensuring that critical research reaches a global audience and promotes collaborative learning. As it converges towards 2024, the journal remains pivotal in shaping the future of toxicology research, providing insights that are essential for developing safer chemicals and protecting environmental health.

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

TOXICOLOGY IN VITRO is a premier journal published by PERGAMON-ELSEVIER SCIENCE LTD, focusing on the latest advancements in the field of toxicology, particularly through in vitro methodologies. With an ISSN of 0887-2333 and an E-ISSN of 1879-3177, this journal serves as a critical platform for researchers aiming to disseminate their findings in toxicology, emphasizing innovative approaches and applications in pharmacology and toxicology. Featuring a commendable impact factor and classified in the second quartile (Q2) for both Medicine (miscellaneous) and Toxicology in 2023, the journal holds a significant position within the academic community, ranking 41st out of 133 in the Toxicology category according to Scopus, representing the 69th percentile. Despite being a subscription-based publication, it continuously attracts submissions from leading scientists worldwide, fostering a vibrant exchange of scientific knowledge. Since its inception in 1987, TOXICOLOGY IN VITRO has consistently aimed to enhance understanding of toxicological challenges, making it an invaluable resource for professionals, students, and researchers dedicated to developing safer pharmaceuticals and understanding the biological pathways influenced by potential toxic agents.

Drug and Chemical Toxicology is a well-respected journal in the fields of toxicology, pharmacology, and public health, published by Taylor & Francis Ltd. Since its inception in 1978, this journal has diligently explored the effects and mechanisms of chemical exposures on health and the environment, fulfilling a crucial role in advancing scientific understanding and safeguarding public health. The journal is indexed across prestigious databases and features an impressive array of articles categorized within the Q2 and Q3 quartiles across various categories in 2023, reflecting its significance in Chemical Health and Safety as well as Environmental and Occupational Health disciplines. With an extensive reach and a focus on interdisciplinary research, Drug and Chemical Toxicology offers a rich repository of original research, reviews, and methodological advancements, catering to a diverse audience of researchers, professionals, and students dedicated to the betterment of safety and health standards. Although not an open-access publication, its articles are widely accessible to the academic community, ensuring that critical innovations and insights are shared for the greater good.

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.